scholarly journals EFFECT OF SUBCUTANEOUS RECOMBINANT HUMAN ERYTHROPOIETIN ON BLOOD PRESSURE IN PRE-DIALYSIS CHRONIC KIDNEY DISEASE (CKD) PATIENTS

2021 ◽  
Vol 71 (1) ◽  
pp. 261-65
Author(s):  
Muhammad Sajid Hussain ◽  
Qasim Raza ◽  
Muhammad Omer Aamir ◽  
Nadia Murtaza ◽  
Sadia Naureen ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Chronic Kidney Disease ◽  
Body Weight ◽  
Kidney Disease ◽  
Recombinant Human Erythropoietin ◽  
Case Series ◽  
Military Hospital ◽  
P Value ◽  
Human Erythropoietin ◽  
Age Range

Objective: To determine the effect of subcutaneous recombinant human erythropoietin on blood pressure in predialysis chronic kidney disease (CKD) patients. Study Design: Case-series descriptive study. Place and Duration of Study: Combined Military Hospital Peshawar, from Mar 2016 to Sep 2016. Methodology: A total of 100 cases were enrolled. Inclusion criteria was patients of 18 to 60 years of both gender & estimated glomerular filtration rate (eGFR) below 30 mL/min/1.73 m2 having Hb <10g/dL and pre-dialysis while Exclusion Criteria was pregnancy or lactation, BP more than 140/90 mmHg, patients on Haemodialysis and worsening renal function. Baseline BP, body weight and eGFR of anaemic chronic kidney disease patients were recorded prior to EPO Alpha therapy. Erythropoiesis-stimulating agents (ESAs) i.e. EPO Alpha (50-100 Units/kg thrice or once weekly) was administered subcutaneously. Subsequent blood pressure, body weight and eGFR monitoring was done after 2 and 4 weeks post EPO Alpha injection. Results: Mean age range was 46.71 years with range of 20-60 years, 73 (73%) were male while 27 (27%) werefemales. Mean ± SD for other quantitative variables like eGFR was 23.12 ± 5.28, Hb levels (g/dL) was 8.62 ± 0.85,Weight (kg) was 56.66 ± 6.62 and duration of CKD was 9.87 ± 4.02. Frequency of Hypertension (post EPO) was 2(2%) and p-value was 0.453. Conclusion: We concluded that the frequency of hypertension in pre-dialysis patients with chronic kidney disease (CKD) receiving recombinant human erythropoietin (rhEPo) subcutaneously (SC) in low doses, is very low, so rhEPo can be used subcutaneously......................

scholarly journals Effectiveness of erythropoietin in correcting anemia in patients of chronic kidney disease.

2020 ◽  
Vol 27 (04) ◽  
pp. 779-783
Author(s):  
Waqas Shakir ◽  
Asim Khurshid ◽  
Muhammad Abu Talib
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Recombinant Human Erythropoietin ◽  
Standard Dose ◽  
Case Series ◽  
Hemoglobin Level ◽  
Human Erythropoietin ◽  
Level Data ◽  
Stage 1 ◽  
Baseline Hemoglobin

Objectives: The anemia of chronic kidney disease (CKD) is commonly normocytic and normochromic. The objective of current study was to see the effectiveness of erythropoietin in correcting anemia in children with CKD. Study Design: Descriptive case series. Setting: Department of Nephrology, at The Children’s hospital and the institute of child health, Multan. Period: From March 2018 to September 2018. Material & Methods: A total of 79 children with CKD were enrolled in this study. A standard dose of erythropoietin 100 IU/kg was given s/c biweekly and after 4 weeks patients were assessed for improvement in Hemoglobin (Hb) level. Data were entered and analyzed using SPSS-18. Results: Of the 79 cases, 48 (60.8%) were boys and 31 (39.2 %) girls. Mean age amongst cases was 9.92 ± 2.60 years and mean weight 19.65 ± 4.71 Kilograms. Mean baseline hemoglobin level of our study cases was 7.88 ± 1.09 gm/dl. Mean hemoglobin level after 4 weeks of therapy with Erythropoietin was 9.22 ± 1.04 gm/dl. Majority of our study cases i.e. 56 (70.88 %) were having stage 1 and 2 of CKD. Correction of anemia (effectiveness) was seen in 72 (91.1%) of our study cases. Conclusion: Recombinant human erythropoietin aid major improvement / correction of anemia in children with CKD. This drug can be safely used in children with CKD disease without any side effects such as hypertension.

Roxadustat Improves Erythropoietin Antibody-Mediated Pure Red Cell Aplasia in a Patient with Hemodialysis

2021 ◽  
pp. 1-4
Author(s):  
Sijia Li ◽  
Xueqin Chen ◽  
Penghua Hu ◽  
Suijing Wu ◽  
Jianchao Ma ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Immunosuppressive Therapy ◽  
Recombinant Human Erythropoietin ◽  
Pure Red Cell Aplasia ◽  
Red Cell ◽  
Common Complication ◽  
Normal Range ◽  
Red Cell Aplasia ◽  
Human Erythropoietin

Anemia is a common complication of chronic kidney disease (CKD). Recombinant human erythropoietin (rHu-EPO) is used extensively in patients with CKD. However, anti-erythropoietin (anti-EPO) antibody has been reported during rHu-EPO treatment, which causes pure red cell aplasia (PRCA). We presented a case of 75-year-old man, who underwent hemodialysis for 2 years. He developed PRCA during rHu-EPO treatment. The rHu-EPO was immediately discontinued, and the patient was given roxadustat treatment. After 6 months of roxadustat treatment, the anti-EPO antibody was disappeared, and hemoglobin recovered normal range. The results suggest that roxadustat can be used to treat patients with anti-EPO antibody-mediated PRCA without immunosuppressive therapy.

scholarly journals Augmented transcripts of kidney injury markers and renin angiotensin system in urine samples of overweight young adults

2020 ◽  
Vol 10 (1) ◽  
Author(s):  
Patricia Rivera ◽  
Catalina Miranda ◽  
Nicole Roldán ◽  
Aaron Guerrero ◽  
Javier Olave ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Chronic Kidney Disease ◽  
Young Adults ◽  
Body Weight ◽  
Kidney Disease ◽  
Kidney Injury ◽  
Tissue Growth ◽  
Mrna Levels ◽  
Simple Method ◽  
Renin Angiotensin

AbstractObesity has been firmly established as a major risk factor for common disease states including hypertension, type 2 diabetes mellitus, and chronic kidney disease. Increased body mass index (BMI) contributes to the activation of both the systemic and intra-tubular renin angiotensin systems (RAS), which are in turn associated with increased blood pressure (BP) and kidney damage. In this cross-sectional study, 43 subjects of normal or increased body weight were examined in order to determine the correlation of BMI or body fat mass (BFM) with blood pressure, fasting blood glucose (FBG), and urinary kidney injury markers such as interleukin-18 (IL-18), connective tissue growth factor (CTGF), neutrophil gelatinase-associated lipocalin, and kidney injury molecule-1 (KIM-1). Our results showed that: (1) subjects with increased body weight showed significantly higher BP, BFM, total body water and metabolic age; (2) BMI was positively correlated to both systolic (R2 = 0.1384, P = 0.01) and diastolic BP (R2 = 0.2437, P = 0.0008); (3) BFM was positively correlated to DBP (R2 = 0.1232, P = 0.02) and partially correlated to urine protein (R2 = 0.047, P = 0.12) and FBG (R2 = 0.07, P = 0.06); (4) overweight young adults had higher urinary mRNA levels of renin, angiotensinogen, IL-18 and CTGF. These suggest that BMI directly affects BP, kidney injury markers, and the activation of the intra-tubular RAS even in normotensive young adults. Given that BMI measurements and urine analyses are non-invasive, our findings may pave the way to developing a new and simple method of screening for the risk of chronic kidney disease in adults.

Sign in / Sign up

Export Citation Format

Share Document